SCHEMBL6898595

SCHEMBL6898595

CNC(=O)[C@H](CC1CCCCC1)NC(=O)N(CCO)CCC(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 7/20 0.41
MMP1 P03956 2/20 0.41
MMP3 P08254 1/20 0.41
CTSK P43235 3/20 0.35
CTSS P25774 2/20 0.35
CTSL P07711 1/20 0.35
CTSB P07858 1/20 0.35
MMP2 P08253 1/20 0.35
MMP9 P14780 1/20 0.34
MMP14 P50281 1/20 0.34
CNR2 P34972 2/20 0.34
PSEN1 P49768 3/20 0.34
PSEN2 P49810 3/20 0.34
APH1B Q8WW43 3/20 0.34
NCSTN Q92542 3/20 0.34
APH1A Q96BI3 3/20 0.34
PSENEN Q9NZ42 3/20 0.34
PSMB11 A5LHX3 1/20 0.34
PSMA7 O14818 1/20 0.34
PSMB1 P20618 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27559967 1.00 CPB2 (0.41) CPB2MMP1MMP3CTSKCTSS
SCHEMBL6897747 0.88 CPB2 (0.44) CPB2CTSKPSEN1PSEN2APH1B
SCHEMBL27559995 0.88 CPB2 (0.44) CPB2CTSKPSEN1PSEN2APH1B
SCHEMBL6897383 0.86 CPB2 (0.38) CPB2MMP1MMP3CTSKCTSS
SCHEMBL27560051 0.86 CPB2 (0.38) CPB2MMP1MMP3CTSKCTSS
SCHEMBL19270372 0.72 MMP1 (0.51) CPB2MMP1MMP3CTSKCTSS
SCHEMBL27562651 0.72 MMP1 (0.50) MMP1MMP3MMP2MMP9
SCHEMBL27543456 0.71 MMP1 (0.52) MMP1MMP3MMP2MMP9MMP14
SCHEMBL6895541 0.71 MMP1 (0.52) MMP1MMP3MMP2MMP9MMP14
SCHEMBL7355743 0.70 CPB2 (0.38) CPB2MMP1MMP3CTSKCTSS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6730784-B2 AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-05-04 US disclosed
US-20020198376-A1 Novel urea derivatives SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-26 US disclosed
US-6492370-B1 Urea derivatives and pharmaceutical compositions thereof SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-12-10 US disclosed
CN-1299344-A Novel urea derivatives SANTEN PHARCEUMATICAL CO LTD (JP) 2001-06-13 CN disclosed
EP-1072591-A1 NOVEL UREA DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2001-01-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020198376-A1 Novel urea derivatives TNF, CTH, CFH CPB2 2264/4885MMP1 3883/4885MMP3 4452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.